MUTANTES DEL VIRUS DE LA RABIA ATENUADOS ESTABLES Y VACUNAS VIVAS DE LOS MISMOS

Mutante del virus de la rabia recombinante que comprende una mutación del gen de la proteína G del genoma viral, comprendiendo dicha mutación al menos una sustitución del codón en el gen de la proteína G del genoma viral que codifica Arg333 en la proteína G con un triplete GAC o un triplete CAC. The present invention relates to recombinant rabies virus mutants comprising a mutation in the viral genome, whereby said mutation comprises at least a substitution of the Arg333 codon in the gene encoding the G protein with a codon that differs by three nucleotides from said Arg333 codon. These rabies virus mutants have a glycoprotein G that comprises an amino acid at position 333 which is encoded by a codon that differs by all three nucleotides from the Arg codon in amino acid position 333 in the glycoprotein of the parental virus. Said recombinant rabies virus mutants are stable and non-pathogenic in immune competent animals and are suitable for use in a live, attenuated anti-rabis vaccine.